Chief Legal Officer of Hims & Hers Health, Inc. (NYSE:HIMS), Boughton Soleil, has sold shares worth over $2.6 million, according to a recent SEC filing. The transactions, which took place on May 30, 2024, involved the sale of Class A Common Stock at prices ranging from $20.00 to $21.40.
The filing indicates that Soleil sold a total of 114,460 shares at an average price of $20.4724, totaling approximately $2,342,144. In a separate transaction, an additional 15,207 shares were sold at an average price of $21.1727, amounting to roughly $322,100. These sales were conducted under a pre-arranged 10b5-1 trading plan, which allows company insiders to set up a predetermined schedule to sell stocks at a time when they are not in possession of material non-public information.
On the same day, the Chief Legal Officer also exercised options to acquire 129,667 shares of Class A Common Stock at a price of $5.01 per share, costing a total of $649,631. Following these transactions, Soleil's ownership in the company stands at 156,855 shares of Class A Common Stock.
Hims & Hers Health, Inc. is a company that operates in the healthcare sector, providing services through offices and clinics of doctors of medicine. The recent transactions by a top executive are part of regular stock trading activities that company insiders may carry out for various personal financial reasons.
Investors often monitor insider trades to gain insight into the company's performance and management's perspective on the stock's value. The details provided in the SEC filings give a clearer picture of the insiders' actions and their potential implications for the company and its shareholders.
InvestingPro Insights
As Hims & Hers Health, Inc. (NYSE:HIMS) experiences insider trading activity, it's crucial for investors to consider current financial data and expert analysis to make informed decisions. According to recent data from InvestingPro, Hims & Hers Health, Inc. boasts a significant market capitalization of $4.4 billion USD, reflecting the company's substantial presence in the healthcare sector.
The company's revenue growth has been impressive, with a 55.65% increase in the last twelve months as of Q1 2024, and a quarterly revenue growth of 45.81% in Q1 2024. This robust top-line expansion could be indicative of Hims & Hers's ability to scale its operations and capture market share effectively. Despite these strong growth figures, the company's P/E ratio stands at -1860, and the adjusted P/E ratio for the last twelve months as of Q1 2024 is 14330.26, which could suggest that the market has high expectations for future earnings growth.
InvestingPro Tips for Hims & Hers Health, Inc. highlight that the company's net income is expected to grow this year, and three analysts have revised their earnings upwards for the upcoming period. This positive sentiment is supported by the company's strong price performance, with a one-week total return of 15.05% and a remarkable six-month total return of 119.93% as of the date referenced. Such performance metrics are essential for investors to consider in the context of recent insider trading activities.
For investors seeking a deeper analysis, there are additional InvestingPro Tips available, including insights on the company's debt levels, liquidity, and profitability forecasts. For more information and to access these valuable tips, visit InvestingPro's HIMS page. Moreover, use coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.